Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been offered in many institutions worldwide since the 1990s. Despite its existence of more than 10 years, this treatment has received heavy criticism for its morbidity and mortality rates. This consequentially resulted in a lack of randomized trials being conducted and translates into a lack of the most reliable form of scientific evidence in clinical research, hence limiting its general acceptance. Objective: To report the morbidity and mortality outcomes of CRS and HIPEC from all institutions performing this treatment as a prelude toward establishing the safety of this treatment for peritoneal carcinomatosis. Methods: A systematic review of relevant studies before August 2008 was performed. Each study was appraised using a predetermined protocol. The quality of studies was assessed. The morbidity and mortality of the treatment were synthesized through a narrative review with full tabulation of results of all included studies. Conclusions: The morbidity and mortality outcomes of CRS and HIPEC are similar to a major gastrointestinal surgery, such as a Whipple's procedure. To derive the maximal benefit of this treatment, careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications of this treatment. (Ann Surg 2009;249: 900 -907) 
P eritoneal carcinomatosis refers to the extensive dissemination of tumors on the inside surface of the abdomen. This clinical entity occurs when a cancer arises either from the peritoneal surface or from the visceral organs, which as a result of uncontrolled proliferation, tumor cells exfoliates and sheds to become circulating within the peritoneal fluid. These tumor cells implant in the upper abdominal regions, bowel surfaces and its mesentery and the pelvis to form plaques of tumor masses that cover vast amount of the peritoneal surface. Results from the EVOCAPE 1, a multicenter French study, which prospectively followed 370 patients with peritoneal carcinomatosis from various primary cancers from diagnosis till death, demonstrated a mean and overall median survival of 6.0 and 3.1 months, respectively. 1 Owing to the poor prognosis and extensive tumor burden that characterizes this fatal malignant progression, it is generally considered an untreatable condition. Aggressive treat-ments are abandoned and management is directed largely at symptom palliation.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined treatment modality that has been available as a treatment option for peritoneal carcinomatosis since the mid 1990s. 2 It is an aggressive approach toward treating this terminal condition with the aims of either curing or prolonging the life of sufferers. The surgical procedure involves stripping of the diseased peritoneum and multiple visceral organ resections, solely aimed at achieving a maximal cytoreduction, leaving a minimal residual tumor volume within the abdomen. Following surgery, a heated chemotherapy perfusate is administered intraoperatively into the abdomen to cover all raw peritoneal surfaces. Intraperitoneal chemotherapy allows a high local concentration of a cytotoxic drug to be achieved for microscopic cytoreduction to target any microscopic residual tumor volume with minimal systemic adverse effects. In addition, hyperthermia has been demonstrated to have a synergistic effect with the chemotherapy and can thus enhances the cytotoxicity of the drug. 3 Although this combined treatment procedure allows extensive cytoreduction, it is not without its own peril.
One of the earliest criticisms of this treatment was that the outcome of patients reported in the early beginning of the carcinomatosis literature, treated by Dr. Sugarbaker at the Washington Cancer Institute, was not reproducible by other investigators. Issues over the varying practices of the techniques of administering HIPEC, variation in the perfusate temperature, chemotherapy dose, and whether an open or closed abdomen technique is more favorable were raised. The high cost associated with the comprehensive management plan which results in limited benefits has also questioned the cost effectiveness of this treatment. Despite the positive survival results demonstrated in the literature of numerous level III evidences from observational clinical series from various institutions and level II evidences from nonrandomized comparative studies, the basis of modern day clinical practice employing evidencebased medicine strategies implies that with only 1 randomized trial of this treatment to date, 4 there is insufficient evidence for the general acceptance of this treatment. Most importantly, the high morbidity and mortality rate has drawn many criticisms about the safety of this treatment. 5 In the United States, the National Cancer Institute, Bethesda, have declared intraperitoneal chemotherapy as the standard of care for Stage III ovarian cancer. 6 The UK National Institute for Clinical Excellence issued guidelines stating that the evidence on the safety and efficacy was not adequate for this procedure to be used without special arrangements for audit and research. 7 In Australia, there are no guidelines pertaining to the treatment of patients with peritoneal carcinomatosis. There exists a lack of acceptance of this treatment. However, being the only institution offering this treatment in Australasia, we receive a large number of patient referrals for treatment consideration. The objec-tive of this study is to conduct a systematic review to assess the morbidity and mortality outcomes of CRS and HIPEC for the treatment of peritoneal carcinomatosis.
METHODS

Literature Search Strategy
Original published studies on the morbidity and mortality of CRS and HIPEC were identified by searching the MEDLINE database (1966 to August 2008) and PubMed (January 1980 -August 2008) using the key words; "hyperthermic," "Intraperitoneal," and "CRS." The search was limited to human articles published in the English language. The reference lists of all retrieved articles were manually reviewed to further identify potentially relevant studies. Expert advice from academic surgeons in Sydney, Australia, were sought to identify any unpublished data. All relevant articles identified were assessed with application of a predetermined selection criterion.
Selection Criteria
The morbidity and mortality outcomes in studies reported by various institutions of the combined treatment modality of CRS and HIPEC were evaluated. In institutions where the morbidity and mortality outcomes were not comprehensively reported, the survival outcomes article was reviewed if the total number of subjects in the study was Ͼ15. If the survival outcomes article reported on a larger number of patients than the morbidity and mortality outcomes report, the article with the larger number of patients was reviewed. This is to ensure that the sample size would not bias the reporting of the morbidity and mortality outcomes from the treatment. All patients had peritoneal carcinomatosis from various primary origins as confirmed by pathologic examination. Studies reporting peritoneal dissemination from sarcomas were excluded to avoid confounding the carcinomatosis literature except if the patients with sarcomatosis were reported within the full morbidity and mortality analysis from that institution. CRS consisted of peritonectomy procedures (anterior parietal peritonectomy, omentectomy Ϯ splenectomy, right and left subphrenic peritonectomy, pelvic peritonectomy, and lesser omentectomy with stripping of the omental bursa Ϯ cholecystectomy) and visceral resections (rectosigmoidectomy, right colectomy, total abdominal colectomy, hysterectomy, and small bowel resection). The type and extent of peritonectomy procedures were not uniformly performed in all the studies included. HIPEC was administered intraoperatively after the cytoreduction. Studies were selected for evaluation if they were level I evidence: randomized controlled trials; level II evidence: nonrandomized controlled clinical trials or well-designed cohort studies; level III evidence: observational studies, as described by the US Preventive Services Task Force.
Data Extraction and Critical Appraisal
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RESULTS
Quantity and Quality of Evidence
Literature search using the above described search strategy through both MEDLINE and PubMed databases identified 155 articles. Through reviewing of the abstracts and references lists, 74 relevant articles were identified. The selection criteria were applied, which resulted in 23 articles that were critically evaluated and tabulated (Table 1) . A further article that is being prepared for submission from our institution is included in this review. Serial publications of articles reporting accumulating number of participants or increased length of follow-up were identified. Only the most recent and definitive update from each institution were included for appraisal and data extraction. In total, the morbidity and mortality outcomes of 24 institutions were reviewed. The level of evidence from these studies were low (mainly level II/III). They comprised mainly of observational studies, nonrandomized case-control analytic studies.
Institutions Offering CRS and HIPEC
The institutions located in the cities of Amsterdam, Lyon, Milan, Pittsburgh, Shizuoka, Sydney, Uppsala, Washington, Winston-Salem, and Villejuif have all reported their morbidity and mortality outcomes. To the best of the authors knowledge, these institutions are led by Dr. Bartlett and coworkers, 26 Deraco and coworkers, 14 Elias et al, 21 Glehen et al, 8 Levine et al, 22 Morris, Sugarbaker et al, 15 Mahteme and coworkers, 27 Yonemura et al, 12 Verwaal and coworkers 23 represent the surgeons who have had extensive experience in performing this procedure ( Table 2) . These institutions are regarded as tertiary high volume institutions and reported between 103 and 460 patients. Most of these procedures are performed on patients with pseudomyxoma peritonei (PMP), colorectal cancer, peritoneal mesothelioma, ovarian cancer, gastric cancer, and less commonly sarcomatosis. A list of some other institutions with a reasonable amount of patient load is listed in Table 1 .
Characteristics of CRS and HIPEC
HIPEC is administered either in an open abdomen (coliseum technique) or a closed abdomen. Depending on the institution, it is performed either before bowel anastomoses or after bowel anastomoses (Table 3 ). In our institution, we performed bowel anastomoses after HIPEC to prevent any tumor cells from being trapped between suture materials. The duration of HIPEC ranges from 30 to 120 minutes at a temperature between 39°C and 44°C. The common chemotherapy drugs of choice in peritoneal mesothelioma is cisplatin, in PMP is mitomycin C, in colorectal cancer is mitomycin C and oxaliplatin, in gastric cancer is mitomycin C, and in ovarian cancer is cisplatin. The doses for mitomycin C ranged from 10 to 120 mg/m 2 and for cisplatin 50 to 250 mg/m 2 ( Table 4 ).
The mean duration of the combined procedure ranged from 4.9 to 10.5 hours. The mean number of peritonectomy procedures performed on each patient ranged from 1.2 to 6.4. The mean number of anastomoses performed per patient ranged from 0.6 to 1.2. The mean number of resections per patient ranged from 0.9 to 3. In some institutions, CRS and HIPEC were followed with an early postoperative intraperitoneal chemotherapy (Table 3) .
Perioperative Morbidity and Mortality Outcomes
The mean length of intensive care unit stay ranged from 1 to 5 days. The mean length of stay in hospital ranged from 7 to 48 days. Across all the reported studies, the overall mortality rates ranged from 0% to 17%. However, this figure might be misrepresented by several smaller studies, which were reviewed. In the institutions which were regarded as tertiary high volume centers, the mortality rates ranged from 0.9% to 5.8%. The common causes of perioperative mortality are sepsis and multiorgan failure as a result of surgical complications ( Table 5 ). The rates of hematological toxicity ranged from 0% to 28%. The overall rate of major or grade III/IV ranged from 0% to 52%. In the institutions which were regarded as tertiary high volume centers, the rate of major or grade III/IV morbidity ranged from 12% to 52%. The reoperation rates following treatment that occurred during the perioperative period ranged from 0% to 23%. Common postoperative complications, comprising of both surgical and chemotherapy related complications, include rates of sepsis ranging from 0 to 14%, fistula 0% to 23%, abscess 0% to 37%, ileus 0% to 86%, perforation 0% to 10%, anastomotic leak 0% to 9%, deep venous thrombosis/pulmonary embolus 0% to 9%, hematological toxicity 0% to 28%, and renal insufficiency 0% to 7% ( Table 6 ).
DISCUSSION
The perception of CRS and HIPEC as a procedure that results in a high morbidity and mortality rate needs to be reexamined. This should be viewed in light of it being an aggressive multidisciplinary approach to treating a terminal and difficult cancer, which was once regarded untreatable. In the last decade, we have seen an unprecedented rise in the number of institutions offering this treatment. Presently, there are more than 10 high volume tertiary institutions worldwide offering this combined treatment and numerous other smaller institutions that are beginning to establish their own peritoneal surface malignancy program. The numerous publications now available in the carcinomatosis literature should address the earliest criticism about the reproducibility of the survival outcomes of patients treated by Dr. Sugarbaker.
To the best of our knowledge, the cost-effectiveness of this treatment has not been evaluated in terms of quality-adjusted life years. Intraperitoneal chemotherapy has been established as an adjuvant treatment following surgery in advanced ovarian cancer following 3 randomized trials that demonstrate a survival benefit compared with intravenous chemotherapy. 31 However, cost-effec- tive analysis of this treatment reported that it was associated with only a modest extension in quality-adjusted survival time but a significant increase in cost compared with conventional treatment. 32 A parallel of this treatment should not be drawn to CRS and HIPEC because this treatment was poorly tolerated as a result of numerous catheter-related complications. 33 We would expect the main expenditure of CRS and HIPEC to be associated with the surgery itself and the hospital stay in the postoperative period. In established institutions, the morbidity rates ranged from 12% to 52% and the mortality rates ranged from 0.9% to 5.8%. It is important for us to distinguish the morbidity and mortality outcomes in high volume tertiary institutions compared with the hospitals where less number of such procedures were performed, as the inverse relationship between hospital volume and surgical mortality has been well documented in various large scale population studies. 34, 35 In these studies, factors associated with major morbidity include performance status, extent of carcinomatosis, duration of surgery, number of peritonectomy procedures performed, number of anastomoses, extent of cytoreduction, number of suture lines, and dose of chemotherapy. 8, 14, 26, 36 There is also a risk of reoperation following the treatment, which is often performed to manage the postoperative complications. Surgical complications such as abscesses, perforation, fistulas, anastomotic leak, and ileus are common postoperative complications following major gastrointestinal surgery. However, whether the occurrence of these events is a result of CRS or a consequence of HIPEC remains to be elucidated. Although locoregional administration of chemoperfusate should reduce the risk of systemic complications of the chemotherapy agent, hematological toxicity, and renal insufficiency still remain a problem. Strategies to standardize the HIPEC techniques and the results of phase I studies that examine the maximum tolerated dose should continue to be investigated. For example, carboplatin, which is known to have fewer side effects when administered intravenously, should be investigated as an alternative to cisplatin. Therefore, the only solution to these complications would be primary prevention, which implies meticulous surgical techniques and secondarily by being extra vigilant during the postoperative period to diagnose and treat any early signs of complications.
Learning curves of this procedure have also been demonstrated. The Dutch group demonstrated that over a period of 10 years, where 323 procedures were performed, the implementation of a patient selection process has resulted in a decrease in peritoneal cancer index but improved rates of complete cytoreduction, decrease in postoperative morbidity rates, and decrease in median duration of hospital stay. 23 In our institution, over a similar period of time, 140 patients were treated. There were reductions in the rates of severe morbidity rate, delayed morbidity, transfusion requirement, duration of operation, and length of intensive care unit stay. 37 These studies demonstrate that over time, a learning curve is observed, which has improved morbidity outcomes.
The Whipple procedure is a procedure, which was once widely debated over its appropriateness due to the severe morbidity and mortality outcomes in comparison to the modest survival benefits. Traditionally, before the 1990s, this procedure was associated with morbidity and mortality rates that were as high as 43% and 30%, respectively. 38, 39 Over the years, with improved operative techniques and judicious postoperative care in the surgical learning curve, the morbidity and mortality rates in several high volume tertiary institutions have declined from about 40% to 1% to 5%, respectively. 34, 35, 38 The 5-year survival rate for pancreatic cancer remains only at 5%. 40 Following a Whipple procedure for pancreatic cancer, the 5-year survival rate is in the order of 0% to 18%. 38, 41 This procedure continues to be offered to patients with pancreatic cancer for both curative and palliative intents. Depending on the primary tumor and compared with traditional treatments of palliative surgery and chemotherapy, CRS and HIPEC are able to offer a considerably greater hope of longer term survival in patients with peritoneal surface malignancy. In PMP, this treatment has been performed with an intention for cure. In sufferers with the disseminated peritoneal adenomucinosis, the more indolent subtype of PMP, compared with peritoneal mucinous carcinomatosis, which is regarded as the more aggressive counterpart, the 5-year survival rates following CRS and HIPEC ranges from 52% to 96%. 42 In colorectal carcinomatosis, following numerous early observational series of poor survival outcomes following treatment in patients with a poor performance status, high peritoneal cancer index, and pres-ence of extra-abdominal metastases, careful patient selection has now been the cornerstone of this treatment. 43 The resultant 5-year survival rate ranges from 22% to 49%. 44 In peritoneal mesothelioma, the 5-year survival rate ranges from 29% to 59%. If untreated, these patients would often succumb to their disease within 6 months. In addition, the terminal phase of illness would be marked with severe pain from ascites and bowel obstruction. The sixth International Peritonectomy Meeting was held in Lyon, France in November 2008. It was advised that patients with tumors confined to the peritoneal cavity who have a good performance status should be referred to a specialized peritonectomy center to assess their suitability for surgery before embarking on palliative systemic chemotherapy alone. To preserve tissue plane and avoid subsequent bowel-related complications due to division of dense adhesions, minimal tissue dissection should be performed at the primary treatment center. This may greatly reduce the risks of bowel injury at the time of definitive peritonectomy and HIPEC procedures, hence improving the quality of life and increasing the best chance of a prolonged survival for these cancer sufferers. In the absence of a more efficacious and proven method of treating peritoneal carcinomatosis whereby tumor biology still poses a significant challenge, the risks of perioperative morbidity and mortality, which are analogous to any other major gastrointestinal surgery (ie, Whipple procedure), needs to be weighed against the benefits of survival. CRS and HIPEC should remain a treatment option to selected patients who are suitable candidates to undergo this treatment in whom a curative and life prolonging treatment is a pursuit, to avoid and delay the inevitable end of this rapidly progressive terminal condition. 
